Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fredrik Piehl

Showing results (1-10 of 302) with videos related to

Pageof 31
Sort By:
JAMA Neurology|January 24, 2017
Multiple Sclerosis-A Tuning Fork Still RequiredFredrik Piehl
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 19, 2022
Low-dose rituximab should be used for treating MS in resource-limited settings: YesFredrik Piehl, Thomas Mathew
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 23, 2018
Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - YesFredrik Piehl, Jan Hillert
Lakartidningen|April 15, 2010
[Newly discovered autoimmune encephalitis wrongly mistaken for mental disease. Anti-NMDA receptor encephalitis puts demands on correct differential diagnosis]Fredrik Piehl, Kajsa Winnerbäck
Neurology|August 8, 2020
Is the treatment of myasthenia gravis improving? Why not ask our patients?Fredrik Piehl, Gil I Wolfe
Frontiers in Immunology|July 3, 2026
Multiple sclerosis and the limits of classical autoimmune theoryAnna Karin Hedström, Fredrik Piehl
Trends in Immunology|December 24, 2002
Harm or heal--divergent effects of autoimmune neuroinflammation?Tomas Olsson, Olle Lidman, Fredrik Piehl
Annals of Neurology|June 18, 2026
Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort StudyThomas Frisell, Sebastian Hedberg, Fredrik Piehl
Lakartidningen|March 25, 2015
[A recently acknowledged state with great variation in severity. NMDAR encephalitis frequently misinterpreted as psychiatric illness]Olafur Sveinsson, Jan Mathé, Fredrik Piehl
Journal of Neurology, Neurosurgery, and Psychiatry|May 14, 2024
Impact of previous treatment history and B-cell depletion treatment duration on infection risk in relapsing-remitting multiple sclerosis: a nationwide cohort studySuvi Virtanen, Fredrik Piehl, Thomas Frisell
Pageof 31

Showing results (1-10 of 302) with videos related to

Sort By:
Pageof 31
JAMA Neurology|January 24, 2017
Multiple Sclerosis-A Tuning Fork Still RequiredFredrik Piehl
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 19, 2022
Low-dose rituximab should be used for treating MS in resource-limited settings: YesFredrik Piehl, Thomas Mathew
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 23, 2018
Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - YesFredrik Piehl, Jan Hillert
Lakartidningen|April 15, 2010
[Newly discovered autoimmune encephalitis wrongly mistaken for mental disease. Anti-NMDA receptor encephalitis puts demands on correct differential diagnosis]Fredrik Piehl, Kajsa Winnerbäck
Neurology|August 8, 2020
Is the treatment of myasthenia gravis improving? Why not ask our patients?Fredrik Piehl, Gil I Wolfe
Frontiers in Immunology|July 3, 2026
Multiple sclerosis and the limits of classical autoimmune theoryAnna Karin Hedström, Fredrik Piehl
Trends in Immunology|December 24, 2002
Harm or heal--divergent effects of autoimmune neuroinflammation?Tomas Olsson, Olle Lidman, Fredrik Piehl
Annals of Neurology|June 18, 2026
Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort StudyThomas Frisell, Sebastian Hedberg, Fredrik Piehl
Lakartidningen|March 25, 2015
[A recently acknowledged state with great variation in severity. NMDAR encephalitis frequently misinterpreted as psychiatric illness]Olafur Sveinsson, Jan Mathé, Fredrik Piehl
Journal of Neurology, Neurosurgery, and Psychiatry|May 14, 2024
Impact of previous treatment history and B-cell depletion treatment duration on infection risk in relapsing-remitting multiple sclerosis: a nationwide cohort studySuvi Virtanen, Fredrik Piehl, Thomas Frisell
Pageof 31